Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial.

Irish AB, Viecelli AK, Hawley CM, Hooi LS, Pascoe EM, Paul-Brent PA, Badve SV, Mori TA, Cass A, Kerr PG, Voss D, Ong LM, Polkinghorne KR; Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group..

JAMA Intern Med. 2017 Jan 3. doi: 10.1001/jamainternmed.2016.8029. [Epub ahead of print]

PMID:
28055065
2.

REPRESENTATIVENESS OF HONEYPOT TRIAL PARTICIPANTS TO AUSTRALASIAN PD PATIENTS.

Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, Liu X, McTaggart S, Morrish AT, Playford G, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW.

Perit Dial Int. 2016 Dec 1. pii: pdi.2016.00065. [Epub ahead of print]

PMID:
27935534
3.

Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis.

Sukkar L, Hong D, Wong MG, Badve SV, Rogers K, Perkovic V, Walsh M, Yu X, Hillis GS, Gallagher M, Jardine M.

BMJ. 2016 Nov 7;355:i5599. doi: 10.1136/bmj.i5599.

4.

Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.

Badve SV, Pascoe EM, Burke M, Clayton PA, Campbell SB, Hawley CM, Lim WH, McDonald SP, Wong G, Johnson DW.

Clin J Am Soc Nephrol. 2016 Jul 21. pii: CJN.00190116. [Epub ahead of print]

PMID:
27445164
5.

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF.

JAMA. 2016 Jul 19;316(3):313-24. doi: 10.1001/jama.2016.9400.

PMID:
27434443
6.

Updates on Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi LS, Ong LM, Irish AB; FAVOURED study team..

Nephrology (Carlton). 2016 May 18. doi: 10.1111/nep.12823. [Epub ahead of print] No abstract available.

PMID:
27188542
7.

Association between Serum Hepcidin-25 and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial.

Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, Olynyk JK, Ferrari P; HERO Study Collaborative Group..

Nephrology (Carlton). 2016 May 12. doi: 10.1111/nep.12815. [Epub ahead of print]

PMID:
27171136
8.

Long-term outcomes of end-stage kidney disease for patients with lupus nephritis.

Zhang L, Lee G, Liu X, Pascoe EM, Badve SV, Boudville NC, Clayton PA, Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW.

Kidney Int. 2016 Jun;89(6):1337-45. doi: 10.1016/j.kint.2016.02.014.

PMID:
27165824
9.

Duration of Hemodialysis Following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure.

Lan PG, Clayton PA, Johnson DW, McDonald SP, Borlace M, Badve SV, Sud K, Boudville N.

Perit Dial Int. 2016 11-12;36(6):623-630.

PMID:
27147291
10.

The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.

Badve SV, Palmer SC, Strippoli GF, Roberts MA, Teixeira-Pinto A, Boudville N, Cass A, Hawley CM, Hiremath SS, Pascoe EM, Perkovic V, Whalley GA, Craig JC, Johnson DW.

Am J Kidney Dis. 2016 Oct;68(4):554-63. doi: 10.1053/j.ajkd.2016.03.418.

PMID:
27138469
11.

APPETITE PREDICTS INTAKE AND NUTRITIONAL STATUS IN PATIENTS RECEIVING PERITONEAL DIALYSIS.

Young V, Balaam S, Orazio L, Bates A, Badve SV, Johnson DW, Campbell KL.

J Ren Care. 2016 Jun;42(2):123-31. doi: 10.1111/jorc.12156.

PMID:
27060338
12.

Center-Specific Factors Associated with Peritonitis Risk-A Multi-Center Registry Analysis.

Nadeau-Fredette AC, Johnson DW, Hawley CM, Pascoe EM, Cho Y, Clayton PA, Borlace M, Badve SV, Sud K, Boudville N, McDonald SP.

Perit Dial Int. 2016 9-10;36(5):509-18. doi: 10.3747/pdi.2015.00146.

PMID:
26764341
13.

Dengue Fever and Takotsubo Cardiomyopathy.

Badve SV, Patil S, Rathod NM, Jumrani CK.

J Assoc Physicians India. 2015 Jul;63(7):67-70.

PMID:
26731834
14.

The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial.

Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Isbel NM, Krum H, Pascoe EM, Perkovic V, Scaria A, Tonkin AM, Vergara LA, Hawley CM; BLOCADE Study Collaborative Group..

Am J Kidney Dis. 2016 Jun;67(6):902-11. doi: 10.1053/j.ajkd.2015.10.029.

PMID:
26717861
15.

End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.

Mallett A, Tang W, Hart G, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, Campbell SB, Clayton PA, Johnson DW.

Am J Nephrol. 2015;42(3):177-84. doi: 10.1159/000440815.

PMID:
26418732
16.

Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.

Zhang L, Liu X, Pascoe EM, Badve SV, Boudville NC, Clayton PA, De Zoysa J, Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW.

Nephrology (Carlton). 2016 May;21(5):387-96. doi: 10.1111/nep.12629.

PMID:
26393772
17.

Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Badve SV, Zhang L, Coombes JS, Pascoe EM, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW; HERO Study Collaborative Group..

Can J Kidney Health Dis. 2015 Aug 18;2:33. doi: 10.1186/s40697-015-0066-5.

18.

The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial.

Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW; HONEYPOT Study Collaborative Group..

Perit Dial Int. 2015 Dec;35(7):712-21. doi: 10.3747/pdi.2014.00206.

PMID:
26224790
19.

Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi SL, Ong ML, Irish AB; FAVOURED Study Team..

Nephrology (Carlton). 2016 Mar;21(3):217-28. doi: 10.1111/nep.12573.

PMID:
26205903
20.

Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.

Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW.

Nephrol Dial Transplant. 2016 Sep;31(9):1425-36. doi: 10.1093/ndt/gfv269. Review.

PMID:
26163881
Items per page

Supplemental Content

Loading ...
Support Center